Ecenofloxacin

Drug Profile

Ecenofloxacin

Alternative Names: CFC-222

Latest Information Update: 30 Aug 2007

Price : $50

At a glance

  • Originator CJ Corporation
  • Class Fluoroquinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 29 Apr 1999 Results from a clinical study has been added to the pharamacokinetic section
  • 08 Jul 1998 The prop INNM for CF 222 is ecenofloxacin
  • 08 Jul 1998 Phase-II clinical trials for Bacterial infections in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top